Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Evaluating e-cigarettes and nicotine pouches for smokers

Official title: Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

Run by Abramson Cancer Center at Penn Medicine · NCT06372899 · Data updated 2026-11-12

This study is testing whether e-cigarettes or nicotine pouches can help long-term smokers quit regular cigarettes and reduce their smoking habits over six weeks.

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment200 (estimated)
SponsorAbramson Cancer Center at Penn Medicine
Academic / other
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedOctober 2, 2024
Main results expectedNovember 2027
Study endsMarch 31, 2028
Registry record updatedMarch 12, 2026
Trial IDNCT06372899 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 21 who smoke at least 5 cigarettes per day and have made multiple unsuccessful quit attempts.

Probably not a fit

Patients who regularly use other nicotine products or have not made prior quit attempts may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether e-cigarettes (ECIGS) or oral nicotine pouches (ONPS) can effectively replace combustible cigarettes among persistent smokers. A total of 200 participants will be randomized to use either ECIGS or ONPS for six weeks after establishing a baseline smoking rate. The study will measure changes in smoking behavior and biomarkers of exposure to assess the harm reduction potential of these noncombustible alternatives. Additionally, subjective rewards and the reinforcing value of ECIGS and ONPS will be evaluated to understand factors influencing switching from cigarettes.

Why it matters

Potential benefit: If successful, this study could provide smokers with effective alternatives to reduce harm associated with combustible cigarette use.

How similar studies have gone: Previous studies have shown promise in using noncombustible nicotine delivery systems for harm reduction, making this approach both relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Able to communicate fluently in English (i.e. speaking, writing, and reading)
2. Male and female smokers who are \> 21 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months.
3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.
4. Have a carbon monoxide (CO) greater than 10 ppm.
5. Not using any forms of nicotine regularly other than cigarettes
6. Be willing to switch to e-cigarettes or nicotine pouches for 6 weeks.
7. Plan to live in the area for the duration of the study.
8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.

Exclusion Criteria:

Smoking Behavior

1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette and nicotine pouch use is defined as greater than 5 days/past 30 days.

   a. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.
2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.
3. Current use of smoking cessation medication
4. Provide a CO breath test reading less than 10 ppm at Intake.

Alcohol and Drug

1. History of substance abuse (other than nicotine dependence) in the past 12 months.
2. Current alcohol consumption that exceeds 20 standard drinks/week.
3. Current use of recreational drugs (other than nicotine and cannabis)
4. Breath alcohol reading (BrAC) greater than .000 at Intake.

Medical

1. Women, including all individuals assigned as "female" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.
2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.

Psychiatric

1\. Lifetime history of schizophrenia or psychosis.

General Exclusion

1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and/or the study design as determined by the Principal Investigator.
2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.
3. Significant non-compliance with protocol and/or study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.

Where it's running

  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Choice-based harm-reduction sampling to help people not ready to quit smoking

    This project will test whether letting smokers who aren't ready to quit choose and try a harm-reduction product (an e-cigarette or a nicotine pouch) leads to less cigarette use over six months than giving a nicotine patch plus lozenge.

    Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07199517

  • How a very-low-nicotine cigarette standard and product prices affect illegal cigarette buying

    This study will test whether requiring very-low-nicotine cigarettes and changing e-cigarette or illegal cigarette prices changes illegal cigarette buying and use of alternatives among adult smokers and dual users.

    Recruiting Virginia Polytechnic Institute and State University · Roanoke, Virginia · NCT07161050

  • Impact of THC on Cigarette Smoking Behavior

    This study is testing how different amounts of THC affect smoking habits and cravings in healthy adults who smoke cigarettes and use cannabis.

    Recruiting Phase 1 Johns Hopkins University · Baltimore, Maryland · NCT06609083

  • Evaluating how flavor affects smokers switching to e-cigarettes

    This study tests whether different e-cigarette flavors can help smokers switch from regular cigarettes to e-cigarettes more easily.

    Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT06264154

  • Using brain stimulation to help people quit smoking

    This study is testing if a special brain treatment can help people quit smoking by focusing on specific areas of the brain that are linked to tobacco addiction.

    Recruiting at 2 sites Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT04903028

  • Smoky Futures: Danish Adolescent Nicotine Use over Time

    This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.

    Recruiting University of Southern Denmark · Copenhagen · NCT07910331

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.